Stem cell biotech Neuroplast already holds an ODD for Traumatic Spinal Cord Injury for which a Phase II clinical trial is ongoing Further applications of Neuro-Cells® are being explored ...

"In our collaboration with Neuroplast to establish the role of cell transplantation in the recovery of individuals with spinal cord injury, it is great to hear that patients are pleased with the ...

Designation paves way for wider applications for several neurodegenerative diseases Designation paves way for wider applications for several neurodegenerative diseases The European Union has granted ...

Neuroplast, a Dutch stem cell technology company, and Hospital Nacional de Parapléjicos de Toledo in Spain, announced positive clinical phase I results after analysis of ten patients suffering from ...

Dublin, May 26, 2021 (GLOBE NEWSWIRE) -- The "Gene and Cell Therapies Targeting CNS Disorders - Market Insights and Market Forecast - 2026" report has been added to ResearchAndMarkets.com's offering.

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Spinal Cord Injury - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The pipeline report reveals ...

Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury An orphan medicinal product designation or orphan disease designation ...

16 patients have been enrolled in a multicenter international, randomized, placebo-controlled, double-blinded Phase II clinical trialGoal: to determine the effect size of Neuro-Cells®, a stem-cell ...